



since

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## PROBING THE BICYCLIC HYDROXYPYRAZOLO[1,5-a]PYRIDINE SCAFFOLD AS A CARBOXYLIC ACID BIOISOSTERE IN THE GABAa RECEPTOR SYSTEM

### This is the author's manuscript

Original	Citation.
Unginar	Challon.

Availability:

This version is available http://hdl.handle.net/2318/147281

Publisher:

wily-vch

Terms of use:

**Open Access** 

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

# PROBING THE BICYCLIC HYDROXYPYRAZOLO[1,5-a]PYRIDINE SCAFFOLD AS A CARBOXYLIC ACID BIOISOSTERE IN THE GABAa RECEPTOR SYSTEM

## Ducime Alex (1), Nielsen Birgitte (2), Lolli Marco L. (1), Frølund Bente (2)

(1) Department of Drug Science and Technology, University of Turin, Via Pietro Giuria, 9 – 10125 Turin, Italy.

(2) Department of Drug Design and Pharmacology, The Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.

Isosteric replacement is a widely used approach within medicinal chemistry for improving properties of a lead compound such as bioavailability, selectivity, and potency. A number of bioisosteric relationships have been established for a number of functional groups including the carboxylic acid. Heterocyles such as tetrazole. 3hydroxyisoxazole. 3-hydroxyisothiazole. 3-hydroxy-1.2.5-thiadiazole. 3-cyclobutene-1.2-dione and the 1.2.5oxadiazole system have been successfully applied as carboxylic acid bioisosteres. Medicinal chemistry programmes have provided an extensive variety of bioisosteric replacements for the carboxylic acid in GABA, the major inhibitory neurotransmitter in the mammalian central nervous system. The 3hydroxypyrazole ring system has previously been shown to be a bioisostere of the carboxylic acid of GABA within the GABA receptor system. In this study, we introduce the bicyclic hydroxypyrazolo[1,5-a]pyridine scaffold (see scaffold 1) as the main backbone of potential ligands for the orthosteric site in the GABA<sub>a</sub> receptor. Apart from mimicking the acidic properties of the carboxylic acid group in GABA and the 3hvdroxvisoxazole in the GABA<sub>a</sub> agonists, THIP and muscimol. the conformational locked hydroxypyrazolo[1,5-a]pyridine moiety offer additional positions for introducing substituents in fixed directions. Taking advantage of this option, we have investigated the effect of introducing the amino containing substituents in different positions of the scaffold (1) and of the corresponding piperidine scaffold (2), thus enabling investigation of the requirement for the mutual position of the functional groups and exposing access to cavities/channels associated to the orthosteric binding site, reaching out for subtypeselectivity.



A series of hydroxypyrazolo[1,5-a]pyridine (1) and hydroxypyrazolo[1,5-a]piperidine (2) derivatives were synthesized and pharmacologically characterized in a  $[{}^{3}H]$ -muscimol displacement assay at native GABA<sub>a</sub> receptors and electrophysiological assays at relevant GABA a receptor subtypes. The synthesis and pharmacological properties are reported and discussed in terms of the structural knowledge available for the GABA<sub>a</sub> receptor.

#### References

- Frølund, B., Ebert, B., Kristiansen, U., Liljefors, T., Krogsgaard-Larsen, P. GABA <sub>A</sub> receptor ligands and their therapeutic potentials. *Curr, Topics Med. Chem.* **2002**, *2*, 817–832.
- Lolli, M.L.; Hansen, S. L.; Rolando, B.; Nielsen, B.; Wellendorph, P.; Madsen, K.; Larsen, O. M.; Kristiansen, U.; Fruttero, R.; Gasco, A.; Johansen, T. N. Hydroxy-1,2,5-oxadiazolyl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Pharmacological Characterization of gamma-Aminobutyric Acid (GABA) Related Compounds. *J. Med. Chem.*, **2006**, *49*(14), 4442-4446.